Uncommon EGFR Mutations in Non–Small Cell Lung Cancer
This publication includes a summary of data on the treatment of patients with EGFR exon 20 insertions in non–small cell lung cancer (NSCLC) and the rapidly changing landscape of HER2-targeted treatment. Thoracic oncologists, who specialize in the treatment of lung cancer, provide key insights on the current management of uncommon EGFR mutations in NSCLC and the emerging treatment landscape of targeted therapies.
EP: 1.Mobocertinib Shows Encouraging ORR in EGFR Exon 20–Mutant Advanced NSCLC
EP: 2.Dr. Fidler on the Potential Utility of ctDNA to Inform Treatment Escalation in Lung Cancer
EP: 3.Dr. Jänne on the Promise of Mobocertinib in EGFR Exon 20–Mutant NSCLC
EP: 4.Dr. Fidler on Balancing Benefit of Novel Agents in EGFR Exon 20–Mutant NSCLC With Toxicities
EP: 5.Dr. Brahmer on Emerging Targeted Therapies in EGFR Exon 20–Mutated Lung Cancer
EP: 6.Dr. Piotrowska on the Utility of Mobocertinib in EGFR Exon 20–Mutant NSCLC
EP: 7.Dr. Heymach on the Efficacy of Mobocertinib in EGFR Exon 20 Insertion–Mutated NSCLC
EP: 8.Dr. Goldberg on the Toxicity Profile of Amivantamab in Metastatic EGFR Exon 20–Mutant NSCLC
EP: 9.Dr. Spira on the Efficacy of Mobocertinib in Metastatic EGFR Exon 20–Mutated NSCLC
EP: 10.Dr. Borghaei on Unique Characteristics of EGFR Exon 20 Insertion Mutations in NSCLC
EP: 11.Heymach Homes in On Emerging Agents in EGFR Exon 20–Mutant NSCLC
Now Viewing
EP: 12.Uncommon EGFR Mutations in Non–Small Cell Lung Cancer
Related Videos
